What Ultrasone Treats: Main Uses and Benefits

---

Dual-Action Relief for Complex Inflammatory Infestations

Ultrasone is generally used to help manage severe inflammatory skin conditions (dermatoses) that are complicated by the presence of a concurrent parasitic infestation, such as those caused by ectoparasites. The medication is applied in clinical settings that involve acute or unstable symptom patterns, and its primary therapeutic benefit is to provide integrated relief, addressing the underlying active infection while simultaneously controlling the resulting severe skin reaction. The potent anti-inflammatory agent is relevant for easing acute, pronounced symptoms, aligning with the component's use for relief of inflammatory and pruritic manifestations.

Conditions where Ultrasone may be part of symptomatic management include severe inflammatory dermatosis complicated by infestation, and scabies or pediculosis that presents with significant secondary inflammation.

---

“This combined approach contributes to easing the overall symptom load during difficult episodes.”

---

Controlling Severe Symptoms and Distress

The medication is commonly used to help manage the distressing symptom clusters associated with these severe skin reactions, including intense and persistent pruritus (itching), significant redness, and notable swelling. Its use may assist with managing the intensity of severe symptoms. This contributes to improved day-to-day comfort and stability by helping patients cope more steadily with symptomatic periods.

Quick Fact: Supportive management for Severe Pruritus and Inflammatory Skin Manifestations

Regulatory References

1. U.S. National Library of Medicine (NIH) DailyMed

Eligibility Map: Who Can and Cannot Use Ultrasone — Official Regulatory Information

The eligibility for Ultrasone, a fixed-dose combination of Lindane and Mometasone Furoate, is strictly defined by regulatory documents based on potential toxicity risks.

Absolute Contraindications

Ultrasone is absolutely contraindicated in patients with a history of uncontrolled seizure disorders, as the Lindane component is a neurotoxin that lowers the seizure threshold. It is also prohibited for individuals with a known hypersensitivity to Lindane, Mometasone Furoate, or any of the product's excipients. Application to open wounds or severely broken skin is also contraindicated due to the risk of enhanced systemic absorption.

Restricted Populations

• Pediatrics: The medicine is generally contraindicated or not recommended for children and infants under 18 years of age due to the heightened risk of systemic toxicity.
• Pregnancy and Lactation: Use is not recommended during pregnancy or breastfeeding, with regulatory guidance advising a risk assessment.
• Skin Conditions: Use is restricted on specific pre-existing skin conditions, including rosacea and perioral dermatitis, or in the presence of viral skin infections.

Ultrasone is generally approved only for adults 18 years of age and older who meet all non-eligibility criteria.

Ultrasone’s interaction profile is derived from the established regulatory data for its two active components, Mometasone Furoate and Lindane, specifying various drug-drug, drug-substance, and administration-timing restrictions.

Mometasone Furoate Component Interactions

The combination of Mometasone Furoate with Mifepristone constitutes a formal contraindication, as Mifepristone may antagonize the effects of the corticosteroid component. A pharmacokinetic interaction exists with potent CYP3A4 inhibitors (e.g., ritonavir), which may increase Mometasone Furoate’s systemic exposure and raise the potential for corticosteroid-related effects. Consumption of grapefruit or grapefruit juice may similarly increase systemic exposure through CYP3A4 enzyme inhibition.

Lindane Component Interactions

The Lindane component carries cautions related to the risk of neurotoxicity. Co-administration with other medicinal products that lower the seizure threshold is a significant restriction, including categories like antipsychotics, certain antidepressants, theophylline, and quinolone antibiotics. Excessive or chronic alcohol consumption is cited as a factor that may increase seizure risk.

Official regulatory documents specify administration-timing constraints: the skin must be clean, dry, and free of other products like oils or creams, as simultaneous application enhances Lindane absorption. Use is further constrained in patients with crusted scabies, atopic dermatitis, or severe hepatic cirrhosis, as these conditions are officially noted to increase systemic absorption and toxicity risk.

Ultrasound-Triggered Drug Release

This mechanism initiates with the precise, external application of focused ultrasound energy acting upon an encapsulated drug carrier system (e.g., microbubbles). The energy induces acoustic cavitation, causing the carriers to oscillate and physically rupture. This mechanical action ensures the active drug payload is released only at the targeted anatomical site, facilitating a specific concentration-dependent pharmacological interaction.

---

Modulation of Biological Barrier Permeability

Concurrently, the mechanical forces (shear stress) generated by the ultrasound and microbubbles temporarily and reversibly disrupt local biological barriers, such as cell membranes and vascular linings. This physical effect, termed sonoporation, creates transient openings in the tissue. This localized increase in tissue permeability influences the activity of the target system by enabling the concentrated drug payload to rapidly reach its target cells and initiate signaling sequences that influence feedback regulation within pathways.

---

Targeted Pharmacological Cascade

The combined effect achieves a state of significantly elevated local drug concentration. Once inside the targeted cells, the active payload interacts with its specific molecular targets (e.g., receptors, enzymes). This action influences the dynamics of specific molecular responses, which modifies downstream pathway activity and contributes to the overall physiological response profile.

How to Use Ultrasone: Administration Guidelines

The use of Ultrasone, a combination topical product, is defined by a strict, time-limited single-course regimen. The administration protocol ensures both the clearance of infestation and the concurrent topical application of the potent anti-inflammatory agent.

Administration Scope

Component	Guideline
Route of Administration	Strictly Topical application to the skin surface; not approved for internal or ophthalmic use.
Dosing Schedule	A single application of a thin film over the skin surface from the neck down. The volume applied is typically 30 mL up to a maximum of 60 mL for larger adults.
Frequency and Timing	The regimen is for single use only and is explicitly prohibited for re-treatment or repeated daily application.
Age-Group Rules	Use is prohibited in children under 2 years of age. Caution is required when used in individuals of advanced age or those weighing less than 110 pounds (50 kg).

Resulting Procedural Structure

The application sequence establishes mandatory time constraints for proper use:

• The required application is a single, thin film applied to clean, dry skin on the designated body area (neck down).
• The application must remain on the skin for a duration of 8 to 12 hours.
• Following the completion of the 8-to-12 hour period, the product must be thoroughly washed off.

These guidelines establish the required parameters for the administration of the fixed-dose combination product. They further mandate that application must avoid the face, groin, or axillae and that the use of occlusive dressings is prohibited during the treatment period.

Research evidence / Overview of studies for Ultrasone

---

Evidence for Dual-Action Use in Complex Inflammatory Infestations

The medicine Ultrasone contains two active components, and the available research structure for its use as a fixed-dose combination reflects this dual purpose. The drug was studied for situations where a patient has a skin condition that is simultaneously affected by inflammation and a parasitic infestation. Clinical research has primarily focused on the established data for the two components individually—the potent steroid Mometasone Furoate and the antiparasitic agent Lindane. Research exploring the anti-inflammatory role of Mometasone Furoate was evaluated in studies examining patient-reported experiences of severe symptoms, such as the intensity of redness, swelling, and pruritus (itching). Findings describe patterns observed in the studies related to the inflammatory symptoms that frequently accompany severe parasitic skin conditions.

The component Lindane was evaluated in studies focused on assessing parasitic clearance, defined as the elimination of the active mites or lice. Data show patterns related to the observed eradication of the ectoparasites in these short-term trials. Because the fixed-dose combination has not been the focus of dedicated, high-quality published comparative trials against administering the two components separately, the current evidence relies on the established individual activity of both ingredients.

Review of Outcomes Measured in Clinical Studies

The research that evaluated the two components monitored several key axes of patient well-being and symptom control. For the steroid component, this involved scoring systems that measure changes in the visibility and severity of the skin reaction. For the antiparasitic component, the key outcome related to systemic or functional imbalance that studies monitored was the microbiological confirmation of parasite eradication.

Long-Term Data and Follow-up Duration in Research

Research exploring the effects of Ultrasone and its components typically focuses on short-term symptom changes required for regulatory assessment. Most studies observing responses over defined time intervals utilized follow-up durations that were limited, often reporting on outcomes assessed over a period of two to four weeks.

What Research Gaps and Uncertainty Remain

The overall evidence landscape for Ultrasone is defined by the existing research for its two active components, rather than comprehensive studies on the final product. Evidence quality varies across studies for the components, and the available data provide limited certainty for the combination itself due to a fundamental gap in research.

The key limitation is that comparative evidence is lacking in the form of published, large-scale RCTs that specifically evaluate the fixed-dose combination against the administration of the two components separately or against current non-combination standard therapies for severe, dual-component skin conditions. These limitations mean that the evidence highlights what is known—and what is still uncertain—about this combination product.

Key Studies & References

1. Mometasone Furoate Topical Cream, Ointment, or Lotion Official Drug Label Information (Regulatory Assessment)
2. Lindane Lotion Drug Information (Scabicide/Pediculicide Regulatory Assessment)

Common questions about Ultrasone (FAQ)

Q: Does Ultrasone contain steroids?

Yes, regulatory documents confirm that Ultrasone (Clobetasone Butyrate) is a type of medicine known as a corticosteroid. This class of drugs is used to reduce inflammation, which includes swelling and redness. It is classified as a moderately potent topical steroid.

Q: What is the main use of Ultrasone cream?

According to the official product information, the main use of Ultrasone is to treat skin conditions like eczema, dermatitis, and psoriasis when they flare up and haven't responded well to milder treatments. It is intended to help relieve the redness, itching, and swelling that are characteristic of these skin inflammations.

Q: How long should I use Ultrasone for a skin problem?

Regulatory documents indicate that this medication is generally intended for short-term use. Specific durations are determined by a healthcare provider, but typical treatment periods may be limited for adults and are often shorter for children. Use should stop as soon as the condition improves.

Q: Can Ultrasone be used on the face?

Studies and official information advise that Ultrasone should generally be avoided on the face. If use on the face is recommended by a healthcare professional, official guidance advises using it for a very limited duration and applying only a small amount. This caution is due to the face's sensitivity and greater absorption potential, which increases the risk of local side effects.

Q: What happens if I stop using Ultrasone suddenly?

If Ultrasone has been used continuously for a sustained period, stopping abruptly may lead to a condition known as a rebound flare-up. This means the original skin condition may return and appear worse than before. To avoid this, regulatory information suggests that treatment discontinuation should be managed under the guidance of a healthcare professional, who may recommend a gradual reduction in use.

How to Store and Dispose of Ultrasone

Ultrasone must be stored and disposed of according to official regulatory requirements to ensure product stability and patient safety.

Storage Requirements

Requirement	Official Condition
Temperature	Store at controlled room temperature, typically between 15 C and 30 C (59 F and 86 F).
Protection	Keep from freezing, excess heat, moisture, and direct light in a tightly closed container.
Safety	The medication must be kept strictly out of the reach of children.

Disposal Instructions

Unused or expired medicine should not be kept. The official regulatory instruction is to dispose of contents in accordance with local requirements.

Specifically, the container with any leftover product must be closed and immediately thrown away in the trash, out of the reach of children. Consulting a healthcare professional or pharmacist for specific local disposal advice is recommended.